A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Have a CD4 count of at least 250 cells/mm3. * Have an HIV count (viral load) of at least 5,000 copies/ml. * Are at least 18 years old. Exclusion Criteria You will not be eligible for this study if you: * Have received prescription or nonprescription medications within 14 days of study entry, or if you will need to take any of these medications during the study. * Have ever received anti-HIV medications. * Test positive for hepatitis B. * Have received a blood (or red blood cell) transfusion within 3 months prior to study entry. * Have severe diarrhea. * Have severe heart, liver, kidney, or neurological (brain and spinal cord) disease. * Have hemophilia or another blood disorder. * Have received certain medications or vaccines within 30 days prior to study entry. * Have received chemotherapy or radiation within 16 days prior to study entry, or if you will need either of these during the study.